Company Overview
| Stock Name | Innovent Bio |
|---|---|
| Stock Code | 01801 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 开发并销售老百姓能买得起的优质药物,拥有全面集成的生物医药平台,专注于肿瘤、眼科、自身免疫和代谢疾病领域的单克隆抗体和其他生物药物研发。 |
| Listing Date | 2018-10-31 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 苏州工业园区东平街168号 |
| Business Address (Hong Kong) | 香港铜锣湾希慎道33号利园一期19楼1901室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.innoventbio.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 13.98 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 500 shares |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2018-10-18 to 2018-10-23 |
| Global Offering Shares | 236,350,000 shares |
| HK Public Offer Shares (Initial) | 23,635,000 shares (10.0%) |
| Public Offer Lots (Initial) | 47,270lots (Pool A23,635lots,Pool B23,635lots) |
| International Placing Shares (Initial) | 212,715,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,118,150,710 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 58.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,304,173,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 152.35B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损人民币716.1百万元 |
| Period-End Cash Balance | 人民币510.5百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018-06 |
|---|---|---|---|
| Revenue | 0 | 18,538 | 4,436 |
| Other income and gains, net | 33,307 | 64,406 | 7,892 |
| Administrative expenses | -52,875 | -79,490 | -73,108 |
| Net finance costs | -53,799 | -57,225 | -32,908 |
| Profit for the year | -544,456 | -716,050 | -57,596 |
| Profit attributable to owners | -504,204 | -562,318 | 43,894 |
Balance Sheet
| Item | 2016 | 2017 | 2018-06 |
|---|---|---|---|
| Cash and cash equivalents | 1,012,991 | 510,471 | 1,887,114 |
| Inventories | 36,631 | 57,722 | 48,980 |
| Total current assets | 1,870,750 | 1,445,755 | 3,837,595 |
| Total assets | 2,815,800 | 2,457,216 | 4,893,774 |
| Total current liabilities | 76,199 | 163,276 | 1,770,182 |
| Total liabilities | 3,774,018 | 4,079,344 | 6,467,649 |
| Total equity | -958,218 | -1,622,128 | -1,573,875 |
| Equity attributable to owners | -1,383,924 | -1,942,548 | -1,573,875 |
| Interest-bearing borrowings | 500,000 | 510,000 | 697,000 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018-06 |
|---|---|---|---|
| Net cash from operating activities | -362,993 | -492,270 | -342,525 |
| Net cash from investing activities | -572,079 | -349,456 | 525,053 |
| Net cash from financing activities | 1,639,605 | 89,406 | 1,119,893 |
| Net increase in cash | 704,533 | -752,320 | 1,302,421 |
| Depreciation of PP&E | 53,347 | 59,853 | 30,491 |
| Purchase of PP&E | -58,444 | -90,971 | -93,470 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 16.58 |
|---|---|
| First Day Open | HK$ 14.3 |
| First Day Change | 18.60% |
| First Day Volume | 46747200.0 |
| First Day Turnover | 704900000.0 |
| Use of Proceeds | 1、52%或約1640.8百萬港元用于撥資正在進行及計劃中的信迪利單抗(IBI-308)臨床試驗、注冊備案的準備事宜及計劃的商業化推出(包括銷售及市場推廣)
2、8%或約252.4百萬港元用于撥資正在進行及計劃中的IBI-305臨床試驗、注冊備案的準備事宜及計劃的商業化推出(包括銷售及市場推廣);
3、4%或約126.2百萬港元用于撥資正在進行及計劃中的IBI-301臨床試驗、注冊備案的準備事宜及計劃的商業化推出(包括銷售及市場推廣);
4、1%或約31.6百萬港元用于撥資正在進行及計劃中的IBI-303臨床試驗、注冊備案的準備事宜及計劃的商業化推出(包括銷售及市場推廣)。
5、25%或約788.8百萬港元用于撥資正在進行及計劃中的其他管線候選藥物的臨床試驗、注冊備案的準備事宜及潛在的商業化推出(包括銷售及市場推廣)。
6、10%或約315.5百萬港元,用作營運資金及一般公司用途。 |
Underwriting Syndicate
Joint Sponsors (4)
Overall Coordinators (5)
Joint Bookrunners (6)
Joint Lead Managers (6)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 195,950,670 HKD | — | 5.90% | — | 6 months | 2019-04-30 |
| 2 | Elbrus Investments Pte. Ltd. | 156,995,400 HKD | — | 4.80% | — | 6 months | 2019-04-30 |
| 3 | LAV Biosciences Fund IV, L.P. | 156,757,740 HKD | — | 4.70% | — | 6 months | 2019-04-30 |
| 4 | Prime Capital Funds | 235,129,620 HKD | — | 7.10% | — | 6 months | 2019-04-30 |
| 5 | Rock Springs Capital Master Fund LP | 39,185,940 HKD | — | 1.20% | — | 6 months | 2019-04-30 |
| 6 | SCC Growth V Holdco L, Ltd. | 470,287,200 HKD | — | 14.20% | — | 6 months | 2019-04-30 |
| 7 | Seacliff (Cayman) Ltd. | 156,757,740 HKD | — | 4.80% | — | 6 months | 2019-04-30 |
| 8 | Vivo Funds | 117,571,800 HKD | — | 3.60% | — | 6 months | 2019-04-30 |
| 9 | 惠理基金管理香港有限公司 | 235,143,600 HKD | — | 7.10% | — | 6 months | 2019-04-30 |
| 10 | 景林资产管理有限公司 | 156,757,740 HKD | — | 4.70% | — | 6 months | 2019-04-30 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 俞德超 | — |
| Company Secretary | 王豔菊、陳濼而 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 主要股东包括FIL Limited(通过Asia Ventures及F-Prime Capital持有约13.97%)、FMR LLC(通过Impresa Fund III Limited Partnership持有约13.97%)、Capital International Private Equity Fund VI, L.P.(通过Seacliff (Cayman) Ltd.持有约6.00%)、Temasek Holdings (Private) Limited(通过TLS Beta持有约5.77%)、Great Biono Fortune LP(持有约8.06%,由俞德超博士控制)。 |
|---|




